Drug Management Tools

September 26, 2022

Drug Management-Tools: Pre-authorizations & Step Therapies

Drug management tools (DMTs) are mechanisms designed to optimize patient outcomes and ensure the most appropriate use of medications, while reducing waste, error, and unnecessary prescription drug use and cost. DMTs are developed by a Pharmacy and Therapeutics (P&T) committee to promote the use of cost-effective and high-quality prescription medication. The P&T committee is comprised of physicians, pharmacists, medical researchers, and other healthcare experts. Examples of DMTs are Prior Authorizations (PA), Step Therapies (ST), Specialty Limits (SL), Quantity Limits (QL), and Age Limits (AL). The P&T Committee is in charge of determining the appropriate DMT for a drug based on the clinical data, FDA package insert, clinical guidelines, and cost-implications. The implementation of a drug management tool ensures that the patient will receive the more effective and safe treatment, while ensuring the best outcomes.


Prior Authorization
A ‘PA’ or prior authorization is a process that reviews if a treatment plan is medically necessary for the patient. This encourages clinically indicated, safe, and cost-effective medication use by allowing coverage when the prescription is adequate to treat the patient's condition. Treatments that may require a prior authorization usually have the following characteristics:


  • Medical treatments that have lower cost and equally effective alternative
  • Drugs and therapies that must be used for a specific health condition
  • Treatments or medications that are frequently misused
  • Medications that are approved only for rare diseases
  • Drugs with dangerous side effects or that can be harmful when combined with other medications
  • Drugs that require previous use of other treatments or laboratory tests


When your pharmacy is processing a claim for a drug that has a drug management tool, the claim will show a ‘
Prior authorization required’ message. The pharmacy will then start the prior authorization process. Usually, medical diagnosis and justification are needed to validate why the treatment is necessary. If clinical criteria is met and the prior-authorization is approved, treatment will be covered. If the pre-authorization is not approved, you and your health care provider may request a reconsideration. 


Step Therapy
Step Therapy is a process where a prerequisite drug is required first before the prescribed drug is covered. This ensures that the patient has tried preferred medications with a proven track record that may be better tolerated, less expensive, or less likely to cause interactions. A Step Therapy follows a mechanism where the adjudication system reviews the medication history to determine if the patient has already been treated with the ‘Step 1’ drug, before approving ‘Step 2’ drugs. This ensures that the most cost-effective alternatives are used before the patient is treated with more expensive and/or non-preferred options.


Don’t more expensive drugs work better?

A higher cost does not automatically mean a better drug. For example, a brand drug may have a less-expensive bioequivalent, generic, or brand alternative that might be an option. Bioequivalent/generic and brand drugs must meet the same standards set by the U.S. Food and Drug Administration (FDA) for safety and effectiveness. Talk to your provider to determine which medication options are best for you.


Drug Management Tools encourage safe and cost-effective medication use, and also help manage the rising cost of prescription drugs for everyone. They also provide a patient benefit that reduces treatment prescription costs providing low-cost alternatives. 


It is recommended that you review your plan benefit documents or call for more information about treatments, services, and supplies that require any DMT under your health plan coverage.




A stethoscope is laying on a piece of paper next to a pen
December 12, 2024
URAC accreditation reflects ProCare Rx’s commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards for PBMs in the industry
By Mc-Rx Team November 15, 2024
Mental health parity and medication adherence
By MC-Rx Clinical Team August 7, 2024
Understanding GLP-1 Medications The landscape of obesity management is evolving, with GLP-1 receptor agonist (RA) medications emerging as a significant player. These FDA-approved drugs have proven effective in helping individuals lose weight, prompting a shift in how they are viewed and covered by health plans. However, the cost implications and strategic decisions surrounding these medications require careful consideration by employer groups and their members. The Case for GLP-1 Medications GLP-1 RAs, originally developed for diabetes management, have shown remarkable efficacy in weight loss. With the growing prevalence of obesity and its associated healthcare costs, there's increasing pressure on health plans to cover these medications. Despite their high cost—annual retail pharmacy expenses can exceed $10,000 per patient—GLP-1 RAs offer potential downstream savings by reducing obesity-related comorbidities such as diabetes, hypertension, and cardiovascular disease​​. Balancing Coverage and Cost Historically, weight loss medications were deemed "lifestyle" drugs and excluded from coverage. However, the rising popularity of GLP-1 RAs and their demonstrated benefits are challenging this perspective. For plan sponsors, the decision to cover these medications involves balancing the high upfront costs with the potential for long-term savings on medical expenses related to obesity. Cost-Containment Strategies For payers choosing to cover GLP-1 medications, several cost-containment strategies can be employed: Formulary Management : Deciding on the placement of these medications within the formulary is crucial. Options range from not covering the drugs to placing them on a high-cost tier with patient cost-sharing. Prior Authorization and Step Therapy : Implementing these measures ensures that only patients with a proper diagnosis (e.g., ICD-10 code for obesity) access these medications, preventing misuse and overutilization. Prerequisite Programs : Requiring participation in wellness or nutrition programs before approving weight loss medications can encourage lifestyle modifications that complement pharmacological treatment. Specialist Restrictions : Limiting prescriptions to weight loss specialists, such as bariatric doctors or endocrinologists, ensures appropriate therapy and monitoring. Duration Limits : Establishing treatment guidelines, such as discontinuing medications if a target weight loss is not achieved within six months, helps manage long-term costs​​. The Role of Brokers and Employer Groups Brokers play a pivotal role in guiding employer groups through the complexities of covering GLP-1 medications. Understanding the cost-benefit dynamics and available cost-containment strategies enables brokers to provide informed recommendations that align with their clients' financial and health objectives. Employer groups, in turn, must weigh the potential benefits of covering these medications against their budgetary constraints and the overall well-being of their workforce. Member Education and Engagement Effective communication with members is essential to ensure they understand the coverage options and adhere to prescribed treatments. Educational initiatives can include: Patient Communication Programs : Providing information on medication adherence, compliance, and lifestyle modifications. Continuing Education : Ongoing programs to keep members informed about the benefits and proper use of weight loss medications. Monitoring and Support : Utilizing pharmacy and medical data to track outcomes and adjust strategies as needed​​. Balance the Scale with Expert Guidance from MC-Rx The adoption of GLP-1 medications for weight loss represents a significant advancement in obesity management. However, the high costs associated with these drugs necessitate careful planning and strategic implementation by brokers, employer groups, and members. By employing robust cost-containment strategies and prioritizing member education, health plans can navigate the financial challenges while delivering meaningful health benefits to their populations. MC-Rx, as a full-service pharmacy benefits manager, offers the expertise and tools to help clients optimize their coverage decisions and manage the complexities of incorporating GLP-1 medications into their health plans. Here are just a few of the GLP-1 strategies we use to shield our clients from excessive costs: Implementation of Drug Management Tools, which is critical to ensure proper utilization for GLP-1s. Strategic Benefit Design, which also protects clients from improper GLP-1 utilization. Clear Member Communication, which is crucial for proper adherence and compliance. When implemented with an existing client, the above-listed strategies helped them achieve $382,000 in cost avoidance for GLP-1s. With the right approach, the benefits of these medications can be realized, contributing to better health outcomes and potentially lowering overall healthcare costs in the long run. For more information on managing GLP-1 medications and other pharmacy benefits, reach out to an MC-Rx expert today .
By MC-Rx Clinical Team August 2, 2024
Mental Health Parity and Medication Adherence
March 21, 2024
MC-Rx, powered by ProCare Rx, has been notified by the Academy of Managed Care Pharmacy (AMCP) of the acceptance of their abstract, “Improving Adherence to HIV PREP via a PBM-Driven Educational Intervention” , for presentation at AMCP 2024 Conference in April.
February 23, 2024
Exploring the rising costs and demands of weight-loss medication and how to combat those costs, significantly lowering drug costs for payors and increasing access for patients who need them.
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 10, 2024
To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention.
September 28, 2023
Increased medication adherence has been linked to better clinical and financial outcomes.
More Posts
Share by: